Head-To-Head Comparison of Obinutuzumab Plus Chlorambucil versus Rituximab Plus Chlorambucil in Patients with Chronic Lymphocytic Leukemia and Coexisting Medical Conditions: Final Stage 2 Results of the CLL11 Trial
During the 2013 Annual Meeting of the American Society of Hematology, Drs Michael Hallek, John G Gribben, and Tait Shanafelt conducted an educational session titled, “Chronic Lymphocytic Leukemia: A New Treatment Era is Born.” Each physician presented various aspects of managing patients with CLL.
A Diagnostic Test for Lupus Based on DNA Methylation Signatures from Peripheral Blood Mononuclear Cells
A definitive diagnosis of systemic lupus erythematosus (SLE) differentiating it from other rheumatic and autoimmune diseases can be challenging, because of a lack of definitive tests with sufficient sensitivity and specificity, as well as the absence of reliable biomarkers.
Pregnancy Complications in Lupus: Retrospective Observational Analysis from a US Health Claims Database
The Epidemiology of Systemic Lupus Erythematosus: Disease Prevalence and Impact on Employment and Work Productivity
Two important studies presented at the American College of Rheumatology annual meeting held in San Diego, California from October 25-30, 2013 analyzed the prevalence of systemic lupus erythematosus (SLE) and lupus nephritis in the US population, as well as the impact of SLE on employment and work productivity in American workers.
Effects of Blisibimod on Renal and Inflammation Biomarkers and on Serum Immunoglobulin and Infection Risk in Patients with Lupus: Results from the PEARL-SC and Open-Label Extension Studies
Blisibimod is a subcutaneously administered inhibitor of B-cell activating factor (BAFF) that has been evaluated in patients with systemic lupus erythematosus (SLE) in the phase 2b PEARL-SC trial and in an ensuing open-label extension study (NCT01305746).
Safety and Efficacy of Epratuzumab in Patients with Lupus Confirmed in a Long-Term Open-Label Extension Study
Epratuzumab is an anti-CD22 monoclonal antibody that modulates B-cell activation and has demonstrated clinically relevant improvements in disease activity in patients with moderate-to-severe systemic lupus erythematosus (SLE) in the phase 2b EMBLEM study (Wallace DJ, et al. Ann Rheum Dis. 2013 Jan 12. Epub ahead of print)
Corticosteroid Use Reduced across 52 Weeks of Belimumab Therapy in Patients with Lupus: Combined Analyses from the BLISS Trials
Postmarketing Experience with Belimumab in Patients with Lupus in Clinical Practice Settings Confirms the Evidence from Clinical Trials
Large-scale phase 3 clinical trials have already demonstrated the clinical efficacy of belimumab (Benlysta) in patients with systemic lupus erythematosus (SLE), which served as the basis for the US Food and Drug Administration approval of this medication for adult patients with active, autoantibody-positive SLE who are receiving standard therapy.
Belimumab Shows Clinical Response and Sustained Reductions in Circulating B Cells and in IgG Levels in Patients with Lupus
Belimumab (Benlysta) is a human monoclonal antibody that inhibits B-lymphocyte stimulator that is approved by the US Food and Drug Administration for the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy.
Page 3 of 4
Results 21 - 30 of 37
Results 21 - 30 of 37